In addition, it would certainly be interesting to investigate the effects of ABT‐199/venetoclax, a more specific inhibitor of BCL‐2, in combination with rituximab or cyclophosphamide in BCL‐2 positive lymphoproliferative disorders associated with EBV. Here, BCL2 is linked to lymphoproliferative syndrome.